Navigation Links
Valeant Pharmaceuticals Files Presentation for Cephalon Stockholders
Date:4/11/2011

gil's patent expiration approaches.  

Cephalon's Board has presided over a loss of value for its stockholders over the last five years and Valeant believes Cephalon's current Board's incentives are not aligned with stockholders.  Over the past 5 years, Cephalon's share price has declined by a compound annual growth rate of -0.5%.  The decline was even more rapid in the year leading up to Valeant's' offer, with the share price declining 19%.(1)  Additionally, Valeant believes the current Board's interests are not fully aligned with shareholders as the Board and management own only 0.25% of basic shares outstanding, and 4 of 9 Board members hold no common shares of Cephalon at all.

We ask that stockholders vote for the new Board slate in the consent solicitation. The proposed Board slate is comprised of highly qualified and well-respected professionals that have the right experience, skills, and qualifications to effectively govern Cephalon at this critical juncture:

  • In-depth understanding of the pharmaceutical business model and pipeline valuation through executive positions and directorships at leading companies, such as GlaxoSmithKline, Quintiles, Meda and Valeant
  • Experience in transformative acquisitions, including Novartis / Alcon, OSI / Astellas, Valeant / Biovail and Glaxo Wellcome / SmithKline Beecham
  • Exceptional corporate governance record, including one winner of the National Association of Corporate Directors Lifetime Achievement Award and another former Director of the Year of the National Association for Corporate Directors

Valeant believes this vote is a referendum on whether stockholders want to pursue Valeant's offer and as such we expect the new Board will enter into negotiations and/or remove the poison pill to facilitate a tender in which the stockholders can make a decision for themselves.

"We remain committed to the c
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Valeant Pharmaceuticals Files Preliminary Consent Solicitation Statement With the SEC
2. Promius Pharma and Valeant Form Collaboration to Market Cloderm® Cream in the United States
3. Valeant Pharmaceuticals Proposes to Acquire Cephalon, Inc. for $73 Per Share in Cash
4. GSK and Valeant Receive European Authorisation for Trobalt (retigabine)
5. Valeant Pharmaceuticals Extends Contract with J. Michael Pearson as CEO and Appoints Him as Chairman of the Board
6. Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
7. Valeant Announces Pricing of Senior Notes
8. Valeant Launches Senior Notes Offering
9. Valeant Pharmaceuticals to Present at RBC Capital Markets 2011 Healthcare Conference
10. Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011
11. Valeant Pharmaceuticals Announces License Of ACZONE® (dapsone) Gel 5% In Canada
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014 Reportlinker.com ... available in its catalogue: Acute Heart ... http://www.reportlinker.com/p0689743/Acute-Heart-Failure-Global-Clinical-Trials-Review-H2-2014.html Acute ... Summary GlobalData,s clinical trial report, ... 2014" provides data on the Acute Heart Failure ...
(Date:9/2/2014)... 2014    - Los ... agentes antitrombóticos no utilizados óptimamente para prevenir la ... presentaciones de GARFIELD-AF en el ESC CONGRESS 2014 ... resultados de pacientes en riesgo de sufrir apoplejía ... Los datos de casi 12.500 pacientes reclutados ...
(Date:9/2/2014)... , -- GARFIELD-AF ... into treatment and outcomes of patients at risk ... Data from nearly 12,500 patients enrolled ... Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, ... fibrillation (AF) patients remain sub-optimal despite the transition ...
Breaking Medicine Technology:Acute Heart Failure Global Clinical Trials Review, H2, 2014 2Acute Heart Failure Global Clinical Trials Review, H2, 2014 3Acute Heart Failure Global Clinical Trials Review, H2, 2014 4Acute Heart Failure Global Clinical Trials Review, H2, 2014 5Acute Heart Failure Global Clinical Trials Review, H2, 2014 6Acute Heart Failure Global Clinical Trials Review, H2, 2014 7Acute Heart Failure Global Clinical Trials Review, H2, 2014 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 2Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 3Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 4Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 5Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 6Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 7Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 8Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 9Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 10Los datos sobre fibrilación atrial muestran agentes antitrombóticos no usados óptimamente para prevenir la apoplejía 11Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... HORSHAM, Pa. , July 28 Teva Respiratory ... efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol ... all efficacy endpoints, demonstrating a statistically significant benefit as compared to ... similar to placebo. , , ...
... BOCA RATON, Fla. , July 28 ... Pharma, the company will market Methylphenidate Solution, the generic ... an Abbreviated New Drug Application (ANDA).  Under the terms ... Tris Pharma, and marketed and distributed by Breckenridge on ...
Cached Medicine Technology:Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 2Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 3Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 4Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 5Teva Respiratory Announces Positive Results From Phase III Trial of BDP HFA Nasal Aerosol in Seasonal Allergic Rhinitis 6Breckenridge Pharmaceutical to Market Methylphenidate Oral Solution Through Agreement With Tris Pharma (Monmouth Junction, NJ) 2
(Date:9/2/2014)... After respective performances in the 2014 World Cup, Brazil and ... Sun Life Stadium. The World Cup allowed the world to ... in Colombian and Brazilian stars. Diehard soccer fans in Miami will ... in early September. , Brazil is currently ranked as the 7th ... nation of the 2014 World Cup was originally favored to win ...
(Date:9/2/2014)... Recently, iFitDress.com, a famous online supplier of ... its range of 2014 seashell wedding dresses . ... prices. A large proportion of them are priced under ... are carefully made by the most skilled workers. Along ... gowns, ivory satin wedding gowns, white halter wedding gowns, ...
(Date:9/2/2014)... 2, 2014 4 pm EDT): In a Viewpoint published ... Association , a team of Boston researchers call for ... quality in the United States. The researchers from the ... University, Harvard University and Boston Children,s Hospital write that ... foods could both help people make meaningful dietary changes ...
(Date:9/2/2014)... The exciting information sessions and AMTC auditions will ... and Bob Wiley. The team of scouts prayerfully ... desire to illuminate entertainment with the light of Christ. ... to join the Bridge Training Program and ... 6, Charlotte Convention Center, 501 South College St., Charlotte, ...
(Date:9/2/2014)... Friendship Village of Schaumburg is ... creates a contemporary marketing presence and visually solidifies ... organization, Friendship Senior Options,” said Stephen A. Yenchek, ... changing the logo, we are making sure that ... and their families.” , Friendship Village is a ...
Breaking Medicine News(10 mins):Health News:Brazil Vs. Colombia Tickets in Miami at Sun Life Stadium: Dazzling Deals Tickets Advises Soccer Fans To Reserve Tickets Early for Brazil vs. Colombia Rematch in Florida 2Health News:Brazil Vs. Colombia Tickets in Miami at Sun Life Stadium: Dazzling Deals Tickets Advises Soccer Fans To Reserve Tickets Early for Brazil vs. Colombia Rematch in Florida 3Health News:Discounted Seashell Wedding Dresses Currently Provided By iFitDress.com 2Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Friendship Village of Schaumburg In Illinois Announces New Logo 2
... According to it, the packaging or covering on the ... they claim to be able to cure. ... area of licensed medicines, the National Rules System was ... no scientific proof to confirm their claims will be ...
... study by the UC Davis researchers states that children from ... choosing better after school snacks. // ,The study by ... September issue of the American Journal of Public Health, has ... the vending machines aren't the only places that need to ...
... an increased risk of developing lymphoma and leukemia. The ... pain does have the risk of cancer. //Researchers speculate ... alpha (TNFá) antagonists, a type of biologic DMARD may ... which work by attaching to and impeding chemical messengers ...
... and vegetable juices may have the unique property or reducing the ... examined more than 2,000 people in the study, which appears in ... ,The researchers found that the risk of Alzheimer's was reduced by ... least three times a week as compared to those who drank ...
... past decade saw a decrease in traumatic head injuries ... according to a new report released on Wednesday.// ... hospital admissions for traumatic head injuries from 1994 to ... 35 per cent since 1994, with children and youth ...
... Research Institute are optimistic about a visual device that may ... , ,During a study to gauge the ... was a marked increase in the way the visually impaired ... which comprises of a small camera, pocket-sized computer and see-through ...
Cached Medicine News:Health News:Doctors worried about Homeopathic licensing 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 2Health News:Kids From Low-Income Groups Could Enhance Their Nutrition By Choosing Better After School Snacks 3Health News:RA Drugs Not Implicated In Cancer 2
... synergy T-EP Developed in collaboration with ... and an exceptionally high standard of ... Multimedia technology and design expertise to ... 2, 5 or 10-channel Medelec Synergy ...
Neuropack Sigma MEB-5500 series evoked potential measuring system is a compact, portable, all-in-one unit....
The Nicolet Bravo is a Multi-application system that can configure to meet the needs of neurophysiology deparent....
... of the MYOHANDY family are probably ... MYOQUICK - SystemPLUS line. Based on ... systems of the ISA 100x EP ... ISA 1002 EP) , 4 channels ...
Medicine Products: